Vericel Corporation (VCEL)
POSITIVEFondamental
70
Prix
$42.91
Capitalisation boursière
$2.20B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$306M
12 derniers mois (au 30/06/2026)
Résultat net
$24M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$25M
Capitaux propres totaux
$355M
Passif total
$133M
Ratio de liquidité général
5.04
Couverture des intérêts
28.49
Dette/EBITDA
4.12
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$44.40
Prix actuel
$42.91
Marge de sécurité
+3.4%
Fourchette de juste valeur
$30.48 - $58.33
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
88.13
ROE
4.7%
Ratio P/B
5.85
P/FCF
35.13
Marge brute
74.6%
ROIC
3.2%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
3.2%
WACC
9.8%
ROIC − WACC
-6.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (19)
- EPS shows upward trend
- Price CAGR 30.41%
- Gross Margin 74.6%
- Debt/Equity ratio
- Operating Margin 6.0%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Revenue Growth 5Y 17.3%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 484.8%
- Earnings Quality (OCF/NI) 2.88
- Share Dilution -0.4%
- Net Margin Trend 7.9% vs 2.9%
- Piotroski F-Score 9/9
Échoué (7)
- ROIC 3.2%
- P/FCF 35.13
- P/B Ratio 5.85
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 6.9%
- PEG Ratio 2.40
Indisponible (1)
- Dividend Payout NaN%
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Dominick C. Colangelo Esq. | CEO, President & Director | 61 |
| Mr. Joseph Anthony Mara Jr. | CFO & Treasurer | 49 |
| Mr. Michael Halpin | Chief Operating Officer | 63 |
| Mr. Sean C. Flynn | Chief Legal Officer | 51 |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer | 63 |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, VP & Corporate Controller | - |
| Mr. Eric Burns | Vice President of Finance & Investor Relations | - |
| Mr. Roland DeAngelis | Chief Marketing Officer | - |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | - |
| Mr. Mike Gilligan | Senior Vice President of Sales | - |
Risque d'audit
4
Risque du conseil
3
Risque de rémunération
6
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for VCEL, sourced from Markets Gazette.
- 2/26/2026NEUTRALVericel (VCEL) Q4 2025 Earnings Call Transcript
Biotechnology firm Vericel (VCEL) held its fourth-quarter 2025 earnings conference call. While specific details from the transcript are not yet available, this event is crucial for investors monitoring the company's financial performance and future outlook. Earnings calls are key moments to assess operational health, revenues, profit margins, and management's guidance. The immediate lack of information prevents an in-depth analysis, but the market will keenly await the data release to understand the impact on key products like MACI and Epicel. Investors should remain vigilant for subsequent communications that could influence the stock's valuation.
via Markets Gazette